Loading...
•
Dec 31, 2024
Intra-Cellular Q4 2024 Earnings Report
Intra-Cellular Therapies reported a net loss for Q4 2024, with CAPLYTA net product sales increasing by 51% compared to the same period in 2023.
Key Takeaways
Intra-Cellular Therapies reported Q4 2024 financial results, featuring a 51% increase in CAPLYTA net product sales to $199.2 million compared to the same period in 2023. The FDA accepted the sNDA submission for lumateperone for adjunctive treatment of major depressive disorder (MDD).
CAPLYTA net product sales grew to $199.2 million in Q4 2024, a 51% increase year-over-year.
The FDA accepted the lumateperone sNDA submission for adjunctive treatment of MDD.
Patient enrollment commenced in two Phase 3 studies in pediatric patients for the treatment of irritability associated with autism spectrum disorder.
Cash, cash equivalents, investment securities, and restricted cash totaled $1.0 billion on December 31, 2024.
Forward Guidance
Intra-Cellular Therapies anticipates potential approval of CAPLYTA for adjunctive treatment of MDD and is expanding its field sales force.
Positive Outlook
- Potential approval of CAPLYTA for adjunctive treatment of MDD.
- Expansion of field sales force in anticipation of potential approval of CAPLYTA for MDD.
- Ongoing patient enrollment in Phase 3 studies for pediatric patients with autism spectrum disorder.
- Advancing ITI-1549 IND enabling studies.
- Patient enrollment ongoing in Phase 2 clinical studies evaluating ITI-1284 in patients with generalized anxiety disorder (GAD).
Challenges Ahead
- There is no guarantee we will complete the pending transaction with Johnson & Johnson within the timeframe we anticipate or at all.
- Challenges associated with execution of our sales activities, which in each case could limit the potential of our product.
- There is no guarantee that a generic equivalent of CAPLYTA will not be approved and enter the market before the expiration of our patents.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...